Equity Details
Price & Market Data
Price: $11.65
Daily Change: -$0.36 / 3.09%
Daily Range: $11.28 - $12.01
Market Cap: $230,528,288
Daily Volume: 343,506
Performance Metrics
1 Week: -1.02%
1 Month: 4.48%
3 Months: -32.07%
6 Months: -28.09%
1 Year: -15.21%
YTD: -42.78%
About Keros Therapeutics, Inc. (KROS)
A concise report on Keros Therapeutics, Inc. (KROS). Price: 11.65, daily change: -$0.36 / 3.09%. Market cap: 230,528,288. YTD performance and 1-month returns.
Company Details
Employees: 78
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.